What is claimed is:

1. A compound selected from Formula **I**:



I

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:

L_1 is S;

R^1 is hydrogen;

R^2 is selected from (a) a 5 to 6 membered heteroaryl wherein the heteroaryl contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein one nitrogen heteroatom may be substituted with oxygen to form an oxide, (b) an 8-10 membered bicyclic cycloalkyl, (c) a 10 membered bicyclic aryl, (d) a 9-10 membered bicyclic heterocycle wherein the heterocycle contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and (e) a 9-10 membered bicyclic heteroaryl wherein the bicyclic heteroaryl contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the heteroaryl, bicyclic cycloalkyl, bicyclic aryl, bicyclic heterocycle and bicyclic heteroaryl are optionally substituted with one or more groups selected from the group consisting of halogen, cyano, oxo, C_1-C_3 alkyl optionally substituted with1 to 3 groups selected from halogen, cyano and OH, C_3-C_6 cycloalkyl, C_1-C_3 alkoxy optionally substituted with 1 to 3 groups selected from halogen, cyano and OH, NHR^a, and a 3 to 6 membered heterocycle optionally substituted with 1 to 3 groups selected from halogen, cyano and OH, wherein the heterocycle contains one or two heteroatoms selected from nitrogen, oxygen and sulfur;

R^3 is selected from the group consisting of:



and

;

X^{10} is CR^9 or O,

X^{11} is CH_2 or O, wherein only one of X^{10} and X^{11} may be O;

R^4 and R^5 are independently selected from hydrogen and C_1-C_3 alkyl;

R^6 is selected from the group consisting of hydrogen, OH and C_1-C_3 alkyl optionally substituted

with an OH group, or

R^6 and R^9 together with the atoms to which they are attached form a 6 membered aryl or a 5 to 6 membered heteroaryl, wherein the heteroaryl contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the aryl and heteroaryl are optionally substituted with 1 or 2 groups selected from the group consisting of halogen, cyano, C_1-C_3 alkyl and C_1-C_3 alkoxy;

R^7 and R^8 are hydrogen, or

R^7 and R^8 together with the atoms to which they are attached form an ethyl bridge such that R^3 is an azabicyclic ring;

R^{99} is hydrogen or deuterium;

x is 1 or 2;

y is 0 or 1; and

R^a is hydrogen or C_1-C_4 alkyl optionally substituted with 1 to 3 groups selected from OH, methoxy, halogen and cyano.

2. The compound of Claim 1, wherein

R^2 is selected from (a) a 5 to 6 membered heteroaryl wherein the heteroaryl contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the heteroaryl is optionally substituted with one or two substituents selected from halogen, C_1-C_3 alkyl optionally substituted with 1 to 3 halogen groups, C_3-C_6 cycloalkyl, C_1-C_3 alkoxy, NHR^a, and a 3 to 6 membered heterocycle optionally substituted with an OH group, wherein the heterocycle contains one or two heteroatoms selected from nitrogen and oxygen; (b) an 8-10 membered bicyclic partially unsaturated cycloalkyl; (c) a 9-10 membered bicyclic partially unsaturated heterocycle, wherein the heterocycle contains one to three heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heterocycle is optionally substituted with one to three groups selected from halogen and oxo; (d) a 9-10 membered bicyclic heteroaryl wherein the bicyclic heteroaryl contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the bicyclic heteroaryl is optionally substituted with 1 to 3 groups selected from halogen and C_1-C_3 alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

3. The compound of Claims 1 or 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of phenyl, 2-chlorophenyl, 3-chlorophenyl, 2,3-dichlorophenyl, 2-amino-3-chloropyridin-4-yl, 2,3-dichloropyridin-4-yl, 3-chloro-2-methylpyridin-4-yl, 3-chloro-2-(4-hydroxypiperidin-1-yl)pyridin-4-yl, 3-chloro-2-(methylamino)pyridin-4-yl, 2,3-dimethylpyridin-4-yl, 2-amino-3-cyclopropylpyridin-4-yl, 2-amino-5-chloropyridin-4-yl, 3-chloro-2-methoxypyridin-4-yl, 3-chloro-2-(trifluoromethyl)pyridin-4-yl, 6-amino-2-(trifluoromethyl)pyridin-3-yl, 2-amino-3-bromopyridin-4-yl, 6-aminopyridin-3-yl, 2-amino-3-fluoropyridin-4-yl, 3-chloro-2-((2-cyano-2-methylpropyl)amino)pyridin-4-yl, 2-amino-3-chloro-1-oxidopyridin-4-yl, 3-chloro-2-((2-hydroxyethyl)amino)pyridin-4-yl, bicyclo[4.2.0]octa-1(6),2,4-trien-2-yl, 2,3-dihydro-1*H*-pyrrolo[3,2-*c*]pyridin-1-yl, 3,3-difluoro-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-

b]pyridin-4-yl, 2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 5-chloro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-3-yl, imidazo[1,2-*a*]pyridin-3-yl, 1*H*-pyrazolo[3,4-*b*]pyridin-3-yl, 1*H*-indazol-3-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-5-yl, imidazo[1,2-*a*]pyrimidin-3-yl, isoquinolin-5-yl and 1*H*-indol-3-yl.

4. The compound of any one of Claims 1 to 3, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R^3 is selected from the group consisting of:





and

5. A compound of Claim 1, selected from the group consisting of:

































































~~, and~~

~~or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.~~

~~6. A compound, or a tautomer, or pharmaceutically acceptable salt thereof, wherein the compound is selected from:~~




















~~, and~~ .

~~7. The compound:~~



and tautomers and pharmaceutically acceptable salts thereof.

8. The compound:



and tautomers and pharmaceutically acceptable salts thereof.

9. The compound:



and tautomers and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.

12. Use of a compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a hyperproliferative disease.

13. A compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in therapy.

14. A compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or

pharmaceutically acceptable salt thereof, for use in the treatment of a hyperproliferative disease.

15. The use or compound of Claims 12 or 14, wherein the hyperproliferative disease is selected from the group consisting of melanoma, juvenile myelomoncytic leukemias, neuroblastoma, Philadelphia chromosome positive chronic myeloid, Philadelphia chromosome positive acute lymphoblastic leukemias, acute myeloid leukemias, myeloproliferative neoplasms (such as Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis), breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck, glioblastoma, anaplastic large-cell lymphoma, thyroid carcinoma, and spitzoid neoplasms.

16. The use or compound of Claims 12 or 14, wherein the hyperproliferative disease is selected from the group consisting of Neurofibromatosis and Noonan Syndrome.

17. The use or compound of Claims 12, 14, 15 or 16, wherein the compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate a hyperproliferative disorder.

18. The use or compound of Claim 17, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

19. The use or compound of Claim 18, wherein the other chemotherapeutic agent is binimetinib.

20. The use or compound of Claim 18, wherein the other chemotherapeutic agent is lorlatinib.

21. The use or compound of Claim 18, wherein the other chemotherapeutic agent is encorafenib.

22. A compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in lung cancer.

23. The compound of Claim 22, wherein the compound is co-administered with at least one other chemotherapeutic agent used in lung cancer, wherein the other chemotherapeutic is lorlatinib.

24. A compound of any one of Claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in colorectal cancer.

25. The compound of Claim 24, wherein the compound is co-administered with at least one other chemotherapeutic agent used in lung cancer, wherein the other chemotherapeutic is encorafenib.

What is claimed is:

1. A compound selected from Formula **I**:



I

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:

L_1 is S;

R^1 is selected from hydrogen and methyl;

R^2 is selected from (a) a 5 to 6 membered heteroaryl wherein the heteroaryl contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein one nitrogen heteroatom may be substituted with oxygen to form an oxide, (b) an 8-10 membered bicyclic cycloalkyl, (c) a 10 membered bicyclic aryl, (d) a 9-10 membered bicyclic heterocycle wherein the heterocycle contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and (e) a 9-10 membered bicyclic heteroaryl wherein the bicyclic heteroaryl contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the heteroaryl, bicyclic cycloalkyl, bicyclic aryl, bicyclic heterocycle and bicyclic heteroaryl are optionally substituted with one or more groups selected from the group consisting of halogen, cyano, oxo, C_1-C_3 alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano and OH, C_3-C_6 cycloalkyl, C_1-C_3 alkoxy optionally substituted with 1 to 3 groups selected from halogen, cyano and OH, NHR^a, and a 3 to 6 membered heterocycle optionally substituted with 1 to 3 groups selected from halogen, cyano and OH, wherein the heterocycle contains one or two heteroatoms selected from nitrogen, oxygen and sulfur;

R^3 is selected from the group consisting of:



and


;

X^{10} is CR^9 or O,

X^{11} is CH_2 or O, wherein only one of X^{10} and X^{11} may be O;

R^4 and R^5 are independently selected from hydrogen and C_1-C_3 alkyl;

R^6 is selected from the group consisting of hydrogen, OH and C_1-C_3 alkyl optionally substituted with an OH group, or

R^6 and R^9 together with the atoms to which they are attached form a 6 membered aryl or a 5 to 6 membered heteroaryl, wherein the heteroaryl contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the aryl and heteroaryl are optionally substituted with 1 or 2 groups selected from the group consisting of halogen, cyano, C_1-C_3 alkyl and C_1-C_3 alkoxy;

R^7 and R^8 are hydrogen, or

R^7 and R^8 together with the atoms to which they are attached form an ethyl bridge such that R^3 is an azabicyclic ring;

R^{99} is hydrogen or deuterium;

x is 1 or 2;

y is 0 or 1; and

R^a is hydrogen or C_1-C_4 alkyl optionally substituted with 1 to 3 groups selected from OH, methoxy, halogen and cyano.

2. The compound of Claim 1, wherein:

R^1 is hydrogen; and

R^2 is selected from (a) a 5 to 6 membered heteroaryl wherein the heteroaryl contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the heteroaryl is optionally substituted with one or two substituents selected from halogen, C_1-C_3 alkyl optionally substituted with 1 to 3 halogen groups, C_3-C_6 cycloalkyl, C_1-C_3 alkoxy, NHR^a, and a 3 to 6 membered heterocycle optionally substituted with an OH

group, wherein the heterocycle contains one or two heteroatoms selected from nitrogen and oxygen; (b) an 8-10 membered bicyclic partially unsaturated cycloalkyl; (c) a 9-10 membered bicyclic partially unsaturated heterocycle, wherein the heterocycle contains one to three heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heterocycle is optionally substituted with one to three groups selected from halogen and oxo; and (d) a 9-10 membered bicyclic heteroaryl wherein the bicyclic heteroaryl contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the bicyclic heteroaryl is optionally substituted with 1 to 3 groups selected from halogen and C_1-C_3 alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

3. The compound of Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.

4. The compound of Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of 2-amino-3-chloropyridin-4-yl, 2,3-dichloropyridin-4-yl, 3-chloro-2-methylpyridin-4-yl, 3-chloro-2-(4-hydroxypiperidin-1-yl)pyridin-4-yl, 3-chloro-2-(methylamino)pyridin-4-yl, 2,3-dimethylpyridin-4-yl, 2-amino-3-cyclopropylpyridin-4-yl, 2-amino-5-chloropyridin-4-yl, 3-chloro-2-methoxypyridin-4-yl, 3-chloro-2-(trifluoromethyl)pyridin-4-yl, 6-amino-2-(trifluoromethyl)pyridin-3-yl, 2-amino-3-bromopyridin-4-yl, 6-aminopyridin-3-yl, 2-amino-3-fluoropyridin-4-yl, 3-chloro-2-((2-cyano-2-methylpropyl)amino)pyridin-4-yl, 2-amino-3-chloro-1-oxidopyridin-4-yl, 3-chloro-2-((2-hydroxyethyl)amino)pyridin-4-yl, bicyclo[4.2.0]octa-1(6),2,4-trien-2-yl, 2,3-dihydro-1*H*-pyrrolo[3,2-*c*]pyridin-1-yl, 3,3-difluoro-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 5-chloro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-3-yl, imidazo[1,2-*a*]pyridin-3-yl, 1*H*-pyrazolo[3,4-*b*]pyridin-3-yl, 1*H*-indazol-3-yl, 1*H*-pyrrolo[2,3-*b*]pyridin-5-yl, imidazo[1,2-*a*]pyrimidin-3-yl, isoquinolin-5-yl and 1*H*-indol-3-yl.

5. The compound of Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R^3 is selected from the group consisting of:















 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  and

 .

6. A compound selected from the group consisting of:

 ,  ,  ,


,

,

,


,

,

,


,

,


,

,


,

,

,

,

,

,

,

,


H2N
N
N
N
N
S
Cl
N+
O-
NH2
,


H2N
N
N
N
N
S
Cl
Cl
N
NH2
,


H2N
N
N
N
N
S
Cl
N
N
H
CN
,


H2N
N
N
N
N
S
,


H2N
N
N
N
N
S
N
,


H2N
N
N
N
N
S
Cl
N
N
H
N
,


H2N
CN
N
N
N
N
S
Cl
N
N
H
,


H2N
CN
N
N
N
N
S
Cl
N
N
H
,


,

,


,

,


,

,

,


,

,

,


,

,

,


,

,


,

,


,

,


,

,

,

,

,

,

,

,

,



,

,

,


,

,


,

,

,

and 
,

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

7. A compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the compound is selected from:


,

,

,


,

,

,


,

,

,


,

,



, 

, and 

.

8. The compound:



and tautomers and pharmaceutically acceptable salts thereof.

9. The compound:



and tautomers and pharmaceutically acceptable salts thereof.

10. The compound:



and tautomers and pharmaceutically acceptable salts thereof.

11. A pharmaceutical composition comprising a compound of Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound of Claim 8, or a tautomer, or pharmaceutically acceptable salt thereof.

13. Compound according to Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is selected from the group consisting of melanoma, juvenile myelomoncytic leukemias, neuroblastoma, Philadelphia chromosome positive acute lymphoblastic leukemias, acute myeloid leukemias, myeloproliferative neoplasms, breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck, glioblastoma, and thyroid carcinoma.

14. The compound of Claim 13, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate a hyperproliferative disorder.

15. The compound of Claim 14, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

16. A pharmaceutical composition comprising a compound of Claim 9, or a tautomer, or pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound of Claim 10, or a tautomer, or pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of Claim 6, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound of Claim 7, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof.

20. The compound of Claim 14, wherein the other chemotherapeutic agent is binimetinib.

21. The compound of Claim 14, wherein the other chemotherapeutic agent is lorlatinib.

22. The compound of Claim 14, wherein the other chemotherapeutic agent is encorafenib.

23. Compound according to Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is lung cancer.

24. The compound of Claim 23, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate the lung cancer.

25. The compound of Claim 24, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

26. The compound of Claim 24, wherein the other chemotherapeutic agent is lorlatinib.

27. Compound according to Claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is colorectal cancer.

28. The compound of Claim 27, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate the colorectal cancer.

29. The compound of Claim 28, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and

brigatinib.

30. The compound of Claim 28, wherein the other chemotherapeutic agent is encorafenib.

31. Compound according to Claim 8, or a tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is selected from the group consisting of melanoma, juvenile myelomoncytic leukemias, neuroblastoma, Philadelphia chromosome positive acute lymphoblastic leukemias, acute myeloid leukemias, myeloproliferative neoplasms, breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck, glioblastoma, and thyroid carcinoma.

32. The compound of Claim 31, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate a hyperproliferative disorder.

33. The compound of Claim 32, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

34. The compound of Claim 32, wherein the other chemotherapeutic agent is binimetinib.

35. The compound of Claim 32, wherein the other chemotherapeutic agent is lorlatinib.

36. The compound of Claim 32, wherein the other chemotherapeutic agent is encorafenib.

37. Compound according to Claim 8, or a tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is lung cancer.

38. The compound of Claim 37, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate the lung cancer.

39. The compound of Claim 38, wherein the other chemotherapeutic agent is

selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

40. The compound of Claim 38, wherein the other chemotherapeutic agent is lorlatinib.

41. Compound according to Claim 8, or a tautomer, or pharmaceutically acceptable salt thereof, for use in treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof, wherein the hyperproliferative disease is colorectal cancer.

42. The compound of Claim 41, wherein the compound is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate the colorectal cancer.

43. The compound of Claim 42, wherein the other chemotherapeutic agent is selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, encorafenib, vemurafenib, dabrafenib, lorlatinib, crizotinib, ceritinib, alectinib and brigatinib.

44. The compound of Claim 42, wherein the other chemotherapeutic agent is encorafenib.

45. The compound:



.

46. A pharmaceutical composition comprising a compound of Claim 45.

47. The compound (*S*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine and tautomers and pharmaceutically acceptable salts thereof.

48. The compound of Claim 47, wherein the compound is (*S*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine and pharmaceutically acceptable salts thereof.

49. The compound of Claim 48, wherein the compound is (*S*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine.

50. The compound (*R*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine and tautomers and pharmaceutically acceptable salts thereof.

51. The compound of Claim 50, wherein the compound is (*R*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine and pharmaceutically acceptable salts thereof.

52. The compound of Claim 51, wherein the compound is (*R*)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine.